

Binding of polyamine-containing toxins in the vestibule of the nicotinic acetylcholine receptor ion channel

M. Gabriele Bixel ^{a,*}, Michael Krauss ^a, Christoph Weise ^a, Maria L. Bolognesi ^b, Michela Rosini ^b, Peter N.R. Usherwood ^c, Carlo Melchiorre ^b, Ferdinand Hucho ^a

^a Institut für Chemie-Biochemie, Fachbereich Biologie, Chemie, Pharmazie (AG Neurochemie), Freie Universität Berlin, Thielallee 63, 14195 Berlin, Germany

^b Dipartimento di Scienze Farmaceutiche, Università di Bologna, 40126 Bologna, Italy

^c Division of Molecular Toxicology, School of Biology, University Park, University of Nottingham, Nottingham NG7 2RD, UK

Abstract

Several wasp venoms contain philanthotoxins (PhTXs) that act as noncompetitive inhibitors (NCIs) on cation-selective ion channels including the nicotinic acetylcholine receptor (nAChR). In the search for a ligand with high affinity and specificity for the nAChR we tested a series of newly developed PhTX analogues. Modulation of the structural elements of PhTXs can significantly influence their binding affinities. This approach resulted in the development of the photolabile compound MR44. In photoaffinity labelling studies ¹²⁵I-MR44 was used to map the ligand-binding site at the *Torpedo californica* nAChR. Upon UV irradiation of the receptor–ligand complex, ¹²⁵I-MR44 was mainly incorporated into the receptor α -subunit. Proteolytic mapping and microsequencing identified the site of ¹²⁵I-MR44 cross-linking within the sequence α His-186 to α Leu-199 that in its C-terminal region partially overlaps with the agonist-binding site. Since bound agonists had only minor influence on ¹²⁵I-MR44 photocross-linking, the site where the hydrophobic head group of ¹²⁵I-MR44 binds must be located outside the zone that is sterically influenced by agonists bound at the nAChR. A possible site of interaction of ¹²⁵I-MR44 would be the N-terminal region of the labelled sequence, in which aromatic amino-acid residues are accumulated. We suggest that the polyamine moiety of ¹²⁵I-MR44 interacts with the high affinity non-competitive inhibitor site deep in the ion channel, while the aromatic ring of this compound binds in the vestibule of the nAChR to a hydrophobic region on the α -subunit that is located close to the agonist binding site. © 2001 Elsevier Science S.A. All rights reserved.

Keywords: Polyamine; Nicotinic acetylcholine receptor; Photoaffinity labelling; Ligand binding site

1. Introduction

The nicotinic acetylcholine receptor (nAChR) belongs to the superfamily of ligand-gated ion channels and is an integral transmembrane protein with a subunit stoichiometry of $\alpha_2\beta\gamma\delta$ [1–3]. The five receptor subunits are arranged around a central pore that opens for cations upon agonist binding. The primary structure of each subunit contains four sequences M1–M4 of particular hydrophobicity, which are long enough to traverse the plasma membrane [4]. The M2 sequences from all subunits have been shown to contribute to the formation of the ion pore [5]. The selectivity filter for cations is formed by several rings of negatively charged

amino acid side chains protruding into the lumen of the pore [6–8].

Two binding sites for agonists and competitive antagonists are located in the extracellular region, mainly on the two α subunits [1] at the α – δ and α – γ interfaces [9,10]. A binding site for non-competitive inhibitors (NCIs), such as triphenylmethylphosphonium (TPMP⁺), has been found in the lumen of the ion channel close to the M2 transmembrane domain [11,12]. Luminal NCIs are assumed to enter the open channel and to bind to different rings within the selectivity filter, thereby inhibiting the ion conductance by sterically plugging the channel pore [13].

The digger wasp *Philanthus triangulum* contains philanthotoxins (PhTXs) as active ingredients in its venom [14,15]. These natural polyamine amides of low molecular weight carry a hydrophobic head group that is

* Corresponding author.

E-mail address: mgbixel@chemie.fu-berlin.de (M.G. Bixel).

MR44 was found to be displaceable by luminal NCIs, indicating that the site of MR44 overlaps with the high affinity-binding site deep in the channel lumen close to the selectivity filter [24]. This finding shows that the polyamine chain of ^{125}I -MR44 is oriented towards the narrow part of the ion channel, as also suggested by previous studies, while the hydrophobic head group of the molecule binds to a hydrophobic sequence that is located close to the agonist-binding site [22].

Acknowledgements

This work was supported by the Biomed2 contract (BMH4-CT97-2395) from the European Community.

References

- [1] J.-P. Changeux, Fidia Res. Found. Neurosci. Award Lect. 4 (1990) 21–168.
- [2] A. Karlin, M.H. Akabas, *Neuron* 15 (1995) 1231–1244.
- [3] F. Hucho, V. Tsetlin, J. Machold, *Eur. J. Biochem.* 239 (1996) 539–557.
- [4] M. Noda, H. Takahashi, T. Tanabe, M. Toyosato, S. Kikuyotani, Y. Furutani, T. Hirose, H. Takashima, S. Inayama, T. Miyata, S. Numa, *Nature* 302 (1983) 538–542.
- [5] F. Hucho, W. Oberthür, F. Lotttspeich, *FEBS Lett.* 205 (1986) 137–142.
- [6] J.-L. Galzi, A.Q. Devillers-Thiéry, N. Hussy, S. Bertrand, J.-P. Changeux, D. Bertrand, *Nature* 359 (1992) 500–505.
- [7] K. Imoto, C. Busch, B. Sakmann, M. Mishina, T. Konno, J. Nakai, H. Bujo, Y. Mori, K. Fukudo, S. Numa, *Nature* 335 (1988) 645–648.
- [8] T. Konno, C. Busch, E. Von Kitzing, K. Imoto, F. Wang, J. Nakai, M. Mishina, S. Numa, B. Sakmann, *Proc. R. Soc. London, Ser. B* 244 (1991) 69–79.
- [9] P. Blount, J.P. Merlie, *Neuron* 3 (1989) 349–357.
- [10] S.E. Pederson, J.B. Cohen, *Proc. Natl. Acad. Sci. USA* 87 (1990) 2785–2789.
- [11] J. Giraudat, M. Dennis, T. Heidmann, J.Y. Cahng, J.-P. Changeux, *Proc. Natl. Acad. Sci. USA* 83 (1986) 2719–2723.
- [12] H.R. Arias, *Biochem. Biophys. Acta* 1376 (1998) 173–220.
- [13] F. Hucho, R. Hilgenfeld, *FEBS Lett.* 257 (1989) 17–23.
- [14] M.E. Adams, R.L. Carney, F.E. Enderlin, E.T. Fu, M.A. Jarema, J.P. Li, C.A. Miller, D.A. Schooley, M.J. Shapiro, V.J. Venema, *Biochem. Biophys. Res. Commun.* 148 (1987) 678–683.
- [15] A.T. Eldefrawi, M.E. Eldefrawi, K. Konno, N.A. Mansour, K. Nakanishi, E. Oltz, P.N.R. Usherwood, *Proc. Natl. Acad. Sci. USA* 85 (1988) 4910–4913.
- [16] P.N.R. Usherwood, I.R. Blagbrough, *Pharmacol. Ther.* 52 (1991) 245–268.
- [17] D. Ragsdale, D.B. Gant, N.A. Anis, A.T. Eldefrawi, M.E. Eldefrawi, K. Konno, R. Miledi, *J. Pharmacol. Exp. Ther.* 251 (1989) 156–156.
- [18] R. Rozental, G.T. Scoble, E.X. Albuquerque, M. Idriss, S. Sherby, D.R. Sattelle, K. Nakanishi, K. Konno, A.T. Eldefrawi, M.E. Eldefrawi, *J. Pharmacol. Exp. Ther.* 349 (1989) 123–130.
- [19] N. Anis, S. Sherby, R. Goodnow, M. Niwa, K. Konno, T. Kallimopoulos, R. Bukownik, K. Nakanishi, P.N.R. Usherwood, A. Eldefrawi, M. Eldefrawi, *J. Pharmacol. Exp. Ther.* 254 (1995) 764–773.
- [20] K. Nakanishi, X. Huang, H. Jiang, Y. Liu, K. Fang, D. Huang, S.-K. Choi, E. Katz, M. Eldefrawi, *Bioorg. Med. Chem.* 5 (1997) 1969–1988.
- [21] M. Rosini, R. Budriesi, M.G. Bixel, M.L. Bolognesi, A. Chiarini, F. Hucho, P. Krogsgaard-Larsen, I. Mellor, A. Minarini, V. Tumiatti, P.N.R. Usherwood, C. Melchiorre, *J. Med. Chem.* 42 (1999) 5212–5223.
- [22] M.G. Bixel, C. Weise, M.L. Bolognesi, M. Rosini, M.J. Brierly, I.R. Mellor, P.N.R. Usherwood, C. Melchiorre, F. Hucho, *J. Biol. Chem.* (2001) in press.
- [23] J.M. Herz, D.A. Johnson, P. Taylor, *J. Biol. Chem.* 262 (1987) 7238–7247.
- [24] M.G. Bixel, M. Krauss, Y. Liu, M.L. Bolognesi, M. Rosini, I.R. Mellor, P.N.R. Usherwood, C. Melchiorre, K. Nakanishi, F. Hucho, *Eur. J. Biochem.* 267 (2000) 110–120.
- [25] P.N. Kao, A.J. Dwork, R.R. Kaldany, M.L. Silver, J. Wideman, S. Stein, A. Karlin, *J. Biol. Chem.* 259 (1984) 11662–11665.
- [26] P.N. Kao, A. Karlin, *J. Biol. Chem.* 261 (1986) 8085–8088.
- [27] J.L. Galzi, F. Revah, D. Black, M. Goeldner, C. Hirth, J.-P. Changeux, *J. Biol. Chem.* 265 (1990) 10430–10437.
- [28] J.B. Cohen, S.D. Sharp, W.S. Liu, *J. Biol. Chem.* 266 (1991) 23354–23364.